Evidence map›Paper›PMID 37305830›Full record

ArticleJournal of medicine and life2023

Abdallah Alzoubi, Samir Al Bashir, Aya Smairat, Ahmad Alrawashdeh, Husam Haddad, Khalid Kheirallah

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicine and life, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. PI3K Signaling at the Crossroads of Lipid Metabolism and Cancer.Advances in experimental medicine and biology · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Abdallah AlzoubiDepartment of Pathological Sciences, College of Medicine, Ajman University, Ajman, United Arab Emirates.
Samir Al BashirDepartment of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Aya SmairatDepartment of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Ahmad AlrawashdehDepartment of Allied Medical Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan.
Husam HaddadDepartment of Pathology and Laboratory Medicine, Ministry of Health, Amman, Jordan.
Khalid KheirallahDepartment of Public Health and Community Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Jordan University of Science and Technology · JOMinistry of Health · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen deprivation therapy (ADT) remains the principal treatment of advanced prostate cancer. However, most patients eventually experience treatment failure, resulting in castrate-resistant prostate cancer (CRPC). Loss of the tumor suppressor gene phosphatase and tensin homolog (

Indexed as

Androgen AntagonistsProstatic NeoplasmsAndrogensCastrationHumansJordanMalePTEN PhosphohydrolaseRetrospective StudiesAndrogen AntagonistsAndrogensPTEN PhosphohydrolasePTEN protein, humanADTcastration resistanceCRPCJordanprostate cancerPTEN

Identifiers

PMID37305830
PMCPMC10251393
OpenAlexW4380290651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.